When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Langerhans cell histiocytosis

Evidence last reviewed: 17 Oct 2026
Topic last updated: 05 Nov 2026

Summary

Definition

History and exam

Key diagnostic factors

  • age <15 years
  • bone pain and/or swelling
  • skin rash
  • polyuria and polydipsia
  • growth or sexual maturation failure
  • vertebra plana
  • hepatosplenomegaly
Full details

Other diagnostic factors

  • cough, dyspnea
  • chest pain
  • orbital abnormalities
  • jaundice
  • ascites
  • cytopenias
  • fever
  • anorexia
  • weight loss
  • irritability
  • ear pain
  • ear discharge
  • hearing loss
  • perforated tympanic membrane
  • headache
  • neurologic signs
  • bloody diarrhea
  • oral mucosa lesions
  • lymphadenopathy
  • thyroid enlargement
Full details

Risk factors

  • smoking
  • family history of thyroid disease
  • perinatal infections
Full details

Diagnostic tests

1st tests to order

  • CBC
  • LFTs
  • serum albumin
  • renal function
  • serum electrolytes
  • serum calcium
  • inflammatory markers
  • endocrine evaluation (adults)
  • BRAF V600E mutation analysis
  • fluorodeoxyglucose PET
  • skeletal survey (children)
  • chest x-ray (children)
  • abdominal ultrasound (children)
  • MRI head with contrast (adults)
  • tissue biopsy
Full details

Tests to consider

  • endocrine evaluation (children)
  • coagulation studies (children)
  • pulmonary function tests
  • echocardiogram
  • high-resolution CT chest
  • audiometry
  • bone marrow aspirate and biopsy
  • quantitative polymerase chain reaction/immunohostochemistry
  • MRI head with contrast (children)
  • MRI spine
  • CT head
Full details

Treatment algorithm

ACUTE

single-system disease: bone involvement

single-system disease: skin involvement

single-system disease: isolated lymph node involvement

single-system disease: lung involvement

single-system disease: CNS involvement

single-system disease: neurodegenerative disease

multisystem disease

ONGOING

relapsed/refractory disease

Contributors

Authors

Nitya Gulati, MD

Assistant Professor of Pediatrics

Department of Pediatrics, Division of Hematology and Oncology

Weill Cornell Medical College-New York Presbyterian Hospital

New York, NY

Disclosures

NG has delivered education lectures on the topics of LCH in children. NG has conducted research and published articles related to use of clofarabine and combination therapies for LCH. NG has published book chapters and review articles on the topics of LCH.

Acknowledgements

Dr Nitya Gulati would like to gratefully acknowledge Dr Gaurav Goyal, Dr Oussama Abla, and Professor Kimo Stine, previous contributors to this topic.

Disclosures

GG has served on the advisory board of Opna Bio LLC, Sobi, and Seagen, received consulting fees from Recordati and received royalties from UpToDate. OA declares that he has no competing interests. KS declares that he serves on the Board of the Histiocytosis Association (a nonprofit organization), has provided advice for a legal firm reviewing a case of LCH, and receives honoraria for membership of advisory boards to Pfizer and Behring.

Peer reviewers

R. Maarten Egeler, MD, PhD

Director of Pediatric Immunology, Hematology, Oncology, Bone Marrow Transplantation, and Autoimmune Diseases

Leiden University Medical Center

Leiden

The Netherlands

Disclosures

RME has previously worked with Dr Abla on a review of LCH. RME is an author of several references cited in this topic.

Rima Jubran, MD, MPH

Assistant Professor of Pediatrics

Keck School of Medicine

University of Southern California

Children's Hospital Los Angeles

Los Angeles, CA

Disclosures

RJ declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Haupt R, Minkov M, Astigarraga I, et al; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013 Feb;60(2):175-84.Full text  Abstract

Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 Apr 28;139(17):2601-21.Full text  Abstract

Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020 Apr 16;135(16):1319-31.Full text  Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: histiocytic neoplasms [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Langerhans cell histiocytosis images
  • Differentials

    • Seborrheic dermatitis
    • Juvenile xanthogranuloma
    • Erdheim-Chester disease
    More Differentials
  • Guidelines

    • Clinical practice guidelines in oncology: histiocytic neoplasms
    • International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer